FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041243019> ?p ?o ?g. }

• W2041243019 endingPage "121" @default.
• W2041243019 startingPage "113" @default.
• W2041243019 abstract "Objectives Current virotherapy strategies for ovarian cancer have been hampered by limitations in target cell infectivity and nonspecific tissue replication. In an effort to circumvent these limitations, we evaluated various CRAds modified to incorporate novel capsid targeting motifs (RGD and chimeric Ad5/3) with a novel tissue-specific promoter (CXCR4). Methods Two novel CRAds (Ad5-CXCR4-F5/3 and Ad5-CXCR4-RGD) were constructed via homologous recombination and verified by PCR and DNA sequencing. The infectivity and viral replication rates of these two CRAds were analyzed via quantitative real-time PCR (QRT-PCR) in cell line experiments using three ovarian cancer cell lines (SKOV3.ip1, Hey, and OV4) and compared to that achieved with a clinical grade CRAd (Δ24-RGD) to be evaluated in a Phase I trial. Cytocidal effects were determined by crystal violet staining in these same cell lines infected with different concentrations of viral particles per cell (0, 0.1, 1, 10, 100, and 500). Additionally, viral replication was evaluated by QRT-PCR in primary ovarian cancer tissue slices from multiple patients with ovarian cancer as well as in primary human normal liver tissue slices in order to establish CRAd selectivity. All experiments incorporated appropriate controls and repeated in triplicate. Results Compared to RGD-capsid CRAds (Δ24-RGD and CXCR4-RGD), the F5/3-capsid CRAd (CXCR4-F5/3) demonstrated significant improvements in infection rates (p=0.025, 0.006, and 0.006) in all ovarian cancer cell lines tested (SKOV3.ip1, Hey, and OV4, respectively). In addition to improved transduction of virus into the cells, the TSP CXCR4-based CRAds demonstrated improved viral replication. Specifically, CXCR4-F5/3 further enhanced viral replication 89-fold (p=0.009, 0.010, 0.003) in the same cancer cell lines. Furthermore, CXCR4-F5/3 showed a 4-log improvement in oncolytic potential over Δ24-RGD. In the ex vivo primary ovarian tissue slices, CXCR4-F5/3 showed a 58-fold improvement in viral replication (p=0.005) compared to the clinical grade Δ24-RGD. Both CXCR4-F5/3 and CXCR4-RGD demonstrated significant reduction of viral replication in normal liver slices (p=0.001). Conclusions These data suggest that a dual targeted approach is feasible for the combined enhancement of infectivity and replication in ovarian cancer with a specificity that was attenuated in normal liver tissues. In fact, CXCR4-F5/3 outperformed our best CRAd agent to date nearly 60-fold in our most stringent ex vivo model of primary ovarian cancer tissue slices and suggests that this novel agent could be useful for the treatment of ovarian cancer." @default.
• W2041243019 created "2016-06-24" @default.
• W2041243019 creator A5009816072 @default.
• W2041243019 creator A5014644110 @default.
• W2041243019 creator A5022987623 @default.
• W2041243019 creator A5031684819 @default.
• W2041243019 creator A5036232956 @default.
• W2041243019 creator A5036647389 @default.
• W2041243019 creator A5042371948 @default.
• W2041243019 creator A5057098914 @default.
• W2041243019 creator A5087227269 @default.
• W2041243019 date "2007-04-01" @default.
• W2041243019 modified "2023-09-27" @default.
• W2041243019 title "Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd)" @default.
• W2041243019 cites W1523680364 @default.
• W2041243019 cites W1531166036 @default.
• W2041243019 cites W1922975641 @default.
• W2041243019 cites W1988876819 @default.
• W2041243019 cites W1991710882 @default.
• W2041243019 cites W2008247134 @default.
• W2041243019 cites W2010397777 @default.
• W2041243019 cites W2025811898 @default.
• W2041243019 cites W2029083442 @default.
• W2041243019 cites W2038325417 @default.
• W2041243019 cites W2041200485 @default.
• W2041243019 cites W2042164584 @default.
• W2041243019 cites W2068724951 @default.
• W2041243019 cites W2079018821 @default.
• W2041243019 cites W2079193018 @default.
• W2041243019 cites W2087773557 @default.
• W2041243019 cites W2099376832 @default.
• W2041243019 cites W2102880982 @default.
• W2041243019 cites W2103810198 @default.
• W2041243019 cites W2119580535 @default.
• W2041243019 cites W2130941707 @default.
• W2041243019 cites W2143113338 @default.
• W2041243019 cites W2146118850 @default.
• W2041243019 cites W2147961945 @default.
• W2041243019 cites W2150110662 @default.
• W2041243019 cites W2156383817 @default.
• W2041243019 cites W2170329311 @default.
• W2041243019 cites W2328421677 @default.
• W2041243019 cites W2383743944 @default.
• W2041243019 doi "https://doi.org/10.1016/j.ygyno.2006.10.057" @default.
• W2041243019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17173958" @default.
• W2041243019 hasPublicationYear "2007" @default.
• W2041243019 type Work @default.
• W2041243019 sameAs 2041243019 @default.
• W2041243019 citedByCount "31" @default.
• W2041243019 countsByYear W20412430192012 @default.
• W2041243019 countsByYear W20412430192013 @default.
• W2041243019 countsByYear W20412430192014 @default.
• W2041243019 countsByYear W20412430192015 @default.
• W2041243019 countsByYear W20412430192016 @default.
• W2041243019 countsByYear W20412430192018 @default.
• W2041243019 countsByYear W20412430192020 @default.
• W2041243019 countsByYear W20412430192022 @default.
• W2041243019 crossrefType "journal-article" @default.
• W2041243019 hasAuthorship W2041243019A5009816072 @default.
• W2041243019 hasAuthorship W2041243019A5014644110 @default.
• W2041243019 hasAuthorship W2041243019A5022987623 @default.
• W2041243019 hasAuthorship W2041243019A5031684819 @default.
• W2041243019 hasAuthorship W2041243019A5036232956 @default.
• W2041243019 hasAuthorship W2041243019A5036647389 @default.
• W2041243019 hasAuthorship W2041243019A5042371948 @default.
• W2041243019 hasAuthorship W2041243019A5057098914 @default.
• W2041243019 hasAuthorship W2041243019A5087227269 @default.
• W2041243019 hasConcept C106358424 @default.
• W2041243019 hasConcept C121608353 @default.
• W2041243019 hasConcept C126322002 @default.
• W2041243019 hasConcept C140704245 @default.
• W2041243019 hasConcept C153911025 @default.
• W2041243019 hasConcept C159047783 @default.
• W2041243019 hasConcept C203233990 @default.
• W2041243019 hasConcept C2522874641 @default.
• W2041243019 hasConcept C2780427987 @default.
• W2041243019 hasConcept C49744831 @default.
• W2041243019 hasConcept C502942594 @default.
• W2041243019 hasConcept C54355233 @default.
• W2041243019 hasConcept C71924100 @default.
• W2041243019 hasConcept C81885089 @default.
• W2041243019 hasConcept C82210918 @default.
• W2041243019 hasConcept C86803240 @default.
• W2041243019 hasConceptScore W2041243019C106358424 @default.
• W2041243019 hasConceptScore W2041243019C121608353 @default.
• W2041243019 hasConceptScore W2041243019C126322002 @default.
• W2041243019 hasConceptScore W2041243019C140704245 @default.
• W2041243019 hasConceptScore W2041243019C153911025 @default.
• W2041243019 hasConceptScore W2041243019C159047783 @default.
• W2041243019 hasConceptScore W2041243019C203233990 @default.
• W2041243019 hasConceptScore W2041243019C2522874641 @default.
• W2041243019 hasConceptScore W2041243019C2780427987 @default.
• W2041243019 hasConceptScore W2041243019C49744831 @default.
• W2041243019 hasConceptScore W2041243019C502942594 @default.
• W2041243019 hasConceptScore W2041243019C54355233 @default.
• W2041243019 hasConceptScore W2041243019C71924100 @default.
• W2041243019 hasConceptScore W2041243019C81885089 @default.
• W2041243019 hasConceptScore W2041243019C82210918 @default.

• next